Quantcast

Latest Macrolides Stories

2014-08-20 16:24:49

Will Provide Business Update on Tuesday, August 26, 2014 PLANTATION, Fla., Aug. 20, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that it will host a conference call to provide an update on Company activities. Access information: Date: Tuesday, August 26, 2014 Time: 4:30 p.m. Eastern daylight time Dial-in numbers: (888) 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ID number:...

2014-08-18 08:29:41

Neurotrope's Collaborator BRNI, Publishes Article in the Journal of Alzheimer's Disease describing correlation of PKCe levels and degree of disease PLANTATION, Fla., Aug. 18, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen,...

2014-08-18 08:29:24

MORGANTOWN, W.Va., Aug. 18, 2014 /PRNewswire-USNewswire/ -- Today, researchers at the Blanchette Rockefeller Neurosciences Institute (BRNI) announced findings from a new study entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts." These new findings offer significant promise for a new therapeutic and diagnostic approach to Alzheimer's disease (AD) that has remained so refractory to effective and early drug treatment. This approach is now the major focus of...

2014-07-29 08:32:50

PLANTATION, Fla., July 29, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C epsilon (PKCe). In preclinical in vivo models, this effect has been shown to play an important role in slowing or reversing AD and restoring cognition, memory and motor skills. The top-line analysis...

2014-07-28 13:28:02

University of Oxford Oxford University scientists have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation. The key results are reported in The Lancet and presented at the World Transplant Congress in San Francisco today. They will help doctors faced with a difficult transplant conundrum: the powerful combinations of...

2014-07-15 08:28:52

Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, July 15, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the medical device industry, will be based in the Company's Boston headquarters. Dr. Barry will focus on three critical...

2014-07-09 08:28:18

-- Newly Issued US Patent Covers Medical Device Coating Process and Compositions -- DURHAM, N.C., July 9, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical devices with precise drug-delivery coatings. These technologies currently are used in producing the company's drug-eluting stent system, MiStent SES(®). The...

2014-07-02 12:13:46

The JAMA Network Journals Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies. The drug sorafenib is the only systemic therapy shown to significantly improve...

2014-06-30 08:29:40

- Result seen across stable and de novo kidney transplant patients - HORSHOLM, Denmark, June 30, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily Envarsus(®) XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated a lower treatment failure rate in African-Americans compared with twice-daily tacrolimus (Prograf(®)). These study...

2014-06-03 16:25:04

HORSHOLM, Denmark, June 3, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S. commercialization of Envarsus(®) XR (tacrolimus extended-release tablets) an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients. Key points: -- Envarsus( )XR is an extended release formulation of tacrolimus being designed for once-daily...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related